US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

VanEck Biotech ETF

240.49

+0.99820.42%

Volume:47.70K

Turnover:11.47M

Market Cap:477.73M

PE:- -

High:241.58

Open:239.94

Low:239.85

Close:239.49

52wk High:244.35

52wk Low:160.91

Shares:1.99M

Float Shares:1.99M

Volume Ratio:5.64

T/O Rate:2.40%

Dividend:0.95

Dividend Rate:0.39%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Amgen’s Pediatric Psoriasis Study Wrap-Up: What Apremilast Safety Data Means for Investors

Revolution Medicines Set to Post 'Strong Launch' for Rasonque, UBS Says

MT Newswires Live

Political and General News Events from August 28

US Regulator Approves Novel Pancreatic Cancer Therapy, Marking Major Win for Independent Biotech

Gilead Breaks Ground on Foster City Biologics Facility in $32 Billion US Investment Push

Why the Drugmaker Behind a Pancreatic Cancer Breakthrough Stayed Independent

Gilead Sciences Director Anthony Welters Disposes of USD 2.64 Million in Common Shares

Gilead’s Bixlenvo approved by FDA for virologically suppressed adults with HIV

US FDA Approves Gilead's Once-Daily Combination Pill for HIV Treatment

U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults with Hiv, Including Those on Complex Regimens

THOMSON REUTERS

Moderna Inc. Stock Slips 4.6%, Underperforms Peers

Amgen’s AMG 691 Phase 1 Trial Targets Key Growth in Asian Markets

Revolution Medicines' Rasonque Label Expands Commercial Opportunity, Oppenheimer Says

MT Newswires Live

Analysts Offer Insights on Healthcare Companies: Verrica Pharmaceuticals (VRCA) and Amgen (AMGN)

HBM Holdings FY26 H1 Profit Falls 11.16% to US$ 64.85 Million; Revenue Rises 20.9% to US$ 122.49 Million

Street View: Revolution's Pancreatic Cancer Drug Nod Sparks a 'transformative' Era

Amgen, AstraZeneca announce Crossing trial showed ‘meaningful’ improvements

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Immuneering (IMRX)

China's JW Therapeutics Interim Revenue Rises 4.7% on Carteyva Sales

JW Cayman Therapeutics FY26 H1 IFRS Loss Narrows 81.14% to RMB 50.4 Million; Revenue Rises 4.7% to RMB 111.4 Million

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/BBH/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BBH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBH\",,,,,undefined,":{"symbol":"BBH","market":"US","secType":"STK","nameCN":"VanEck Biotech ETF","latestPrice":240.49,"timestamp":1788373474734,"preClose":239.4918,"halted":0,"volume":47697,"delay":0,"changeRate":0.004167992390553652,"floatShares":1986503,"shares":1986503,"eps":0,"marketStatus":"Trading","change":0.9982,"latestTime":"09-02 14:27:03 EDT","open":239.94,"high":241.58,"low":239.85,"amount":11473302.52926,"amplitude":0.007224,"askPrice":242.11,"askSize":200,"bidPrice":241.88,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788379200000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":239.4918,"sharesOutstanding":1976503,"nav":236.27832,"aum":469367592.63,"dividendRate":0.003933,"bidAskSpread":0.001117,"preHourTrading":{"tag":"盘前","latestPrice":239.49,"preClose":239.4918,"latestTime":"04:56 EDT","volume":1,"amount":239.49,"timestamp":1788339417440,"change":-0.0018,"changeRate":-0.000008,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":239.0965,"preClose":239.4918,"latestTime":"16:23 EDT","volume":18,"amount":4311.9544,"timestamp":1788294232639,"change":-0.3953,"changeRate":-0.001651,"amplitude":0},"volumeRatio":5.638153,"impliedVol":0.1934,"impliedVolPercentile":0.4921},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBH\",,,,,undefined,":{"symbol":"BBH","floatShares":1986503,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":5.638153,"shares":1986503,"dividePrice":0.9459,"high":241.58,"amplitude":0.007224,"preClose":239.4918,"low":239.85,"week52Low":160.91,"pbRate":"--","week52High":244.345,"institutionHeld":0,"latestPrice":240.49,"committee":-0.333333,"eps":0,"divideRate":0.003933,"volume":47697,"delay":0,"ttmEps":0,"open":239.94,"prevYearClose":189.2649,"prevWeekClose":236.4764,"prevMonthClose":236.396,"prevQuarterClose":203.2373,"fiveDayClose":242.67,"twentyDayClose":210.4939,"sixtyDayClose":186.0541},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BBH\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"BBH","amount":0.9565,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"VanEck Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2024-12-23","symbol":"BBH","amount":1.2517,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"VanEck Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-24","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-24"},{"date":"2023-12-18","symbol":"BBH","amount":0.7127,"announcedDate":"2023-12-15","type":"dividend","market":"US","newRecordDate":"2023-12-19","defaultRemindTime":1702909800000,"name":"VanEck Biotech ETF","recordDate":"2023-12-22","payableDate":"2023-12-19","currency":"USD","dateTimestamp":1702875600000,"payDate":"2023-12-22"},{"market":"US","date":"2022-12-19","symbol":"BBH","amount":0.7488,"defaultRemindTime":1671460200000,"name":"VanEck Biotech ETF","recordDate":"2022-12-23","payableDate":"2022-12-20","currency":"USD","type":"dividend","dateTimestamp":1671426000000},{"market":"US","date":"2021-12-20","symbol":"BBH","amount":0.3972,"defaultRemindTime":1640010600000,"name":"VanEck Vectors Biotech ETF","recordDate":"2021-12-27","payableDate":"2021-12-21","currency":"USD","type":"dividend","dateTimestamp":1639976400000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BBH\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-19","recordDate":"2016-12-21","paymentDate":"2016-12-23","value":0.327,"currency":"USD"},{"executeDate":"2018-12-20","recordDate":"2018-12-21","paymentDate":"2018-12-27","value":0.006,"currency":"USD"},{"executeDate":"2019-12-23","recordDate":"2019-12-24","paymentDate":"2019-12-30","value":0.4724,"currency":"USD"},{"executeDate":"2020-12-21","recordDate":"2020-12-22","paymentDate":"2020-12-28","value":0.6079,"currency":"USD"},{"executeDate":"2021-12-20","recordDate":"2021-12-21","paymentDate":"2021-12-27","value":0.3972,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BBH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BBH\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2663225097","title":"Amgen’s Pediatric Psoriasis Study Wrap-Up: What Apremilast Safety Data Means for Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2663225097","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663225097?lang=en_us&edition=fundamental","pubTime":"2026-08-29 00:30","pubTimestamp":1787934627,"startTime":"0","endTime":"0","summary":"Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen’s latest psoriasis study update spotlights apremilast (AMG 407) for ki...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/amgens-pediatric-psoriasis-study-wrap-up-what-apremilast-safety-data-means-for-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/amgens-pediatric-psoriasis-study-wrap-up-what-apremilast-safety-data-means-for-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B2B36J28.USD","LU2089984988.USD","LU0868494617.USD","LU2468319806.SGD","TBXU","BK4139","LU0289739699.SGD","BIB","BK4211","LU0109394709.USD","IE0009355771.USD","BK4585","LU2242652126.USD","BK4533","SG9999001440.SGD","BK4588","AMGN","IBBQ","IE00BFTCPJ56.SGD","BBH","IE00BJJMRZ35.SGD","BK4566","IE00B4R5TH58.HKD","LU0058720904.USD","LU0889565916.HKD","BK4581","LU1983299246.USD","PJP","IE00BJT1NW94.SGD","LU2112291526.USD","PBE","IBB","LU0320765992.SGD","LU1061106388.HKD","LU1023059063.AUD","LU1571399168.USD","LU0122379950.USD","IE0002141913.USD","BK4534","ISBC","LU1057294990.SGD","BK4599","LU2242646821.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663975310","title":"Revolution Medicines Set to Post 'Strong Launch' for Rasonque, UBS Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2663975310","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663975310?lang=en_us&edition=fundamental","pubTime":"2026-08-29 00:18","pubTimestamp":1787933923,"startTime":"0","endTime":"0","summary":"Revolution Medicines  should post \"strong launch numbers\" for pancreatic cancer drug Rasonque , which would serve as a key driver of its 2026 and 2027 revenue, UBS Securities said in a Thursday note.The US Food and Drug Administration approved Rasonque for the treatment of adult patients with metastatic pancreatic adenocarcinoma, with the company to price the therapy at $39,800 for a 30-day supply.Street consensus for the company's 2026 and 2027 revenue already increased following the approval, but the updated projections remain achievable, UBS said. Revolution Medicines already had 2,000 patients on its expanded access program as of Q2, the brokerage noted.The consensus is for $152 million revenue in 2026 and $1.10 billion in 2027, while UBS estimates $193 million in 2026 and $1.91 billion in 2027, according to the note.UBS also noted the upcoming phase 3 data on daraxonrasib in non-small cell lung cancer by year-end 2027 as Revolution Medicines' next major clinical catalyst.UBS raise","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B2B36J28.USD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","IE0009355771.USD","IE00BJT1NW94.SGD","LU0889565916.HKD","RVMD","IE0002141913.USD","CANC","LU0109394709.USD","PTH","BBH","BK4139","IDNA","IE00BJJMRZ35.SGD","LU0320765992.SGD","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662098405","title":"Political and General News Events from August 28","url":"https://stock-news.laohu8.com/highlight/detail?id=2662098405","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662098405?lang=en_us&edition=fundamental","pubTime":"2026-08-28 20:30","pubTimestamp":1787920229,"startTime":"0","endTime":"0","summary":"DIARY-Political and General News Events from August 28Aug 28 (Reuters)-For other diaries, please see:Political andGeneral NewsPOL/DIARYTop Economic EventsM/DIARYEmerging Markets Economic EventsEMRG/DI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nL4N44P0YN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","LU2468319806.SGD","LU0058720904.USD","IE00BJT1NW94.SGD","IE00B2B36J28.USD","IBBQ","LU2242652126.USD","BK4585","IE00BJJMRZ35.SGD","PJP","TBXU","IE00B4R5TH58.HKD","LU1057294990.SGD","LU0122379950.USD","IE0009355771.USD","BK4533","IE00BFTCPJ56.SGD","LU2112291526.USD","LU0868494617.USD","LU0320765992.SGD","BK4588","IE0002141913.USD","BK4566","LU1571399168.USD","BK4599","LU1023059063.AUD","LU2242646821.SGD","PBE","LU1061106388.HKD","LU0289739699.SGD","BK4534","IBB","LU0889565916.HKD","SG9999001440.SGD","AMGN","BIB","LU1983299246.USD","BK4139","LU2089984988.USD","BBH","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145744656","title":"US Regulator Approves Novel Pancreatic Cancer Therapy, Marking Major Win for Independent Biotech","url":"https://stock-news.laohu8.com/highlight/detail?id=1145744656","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145744656?lang=en_us&edition=fundamental","pubTime":"2026-08-28 18:24","pubTimestamp":1787912643,"startTime":"0","endTime":"0","summary":"The U.S. Food and Drug Administration has officially approved Revolution Medicines' self-developed pancreatic cancer treatment, Rasonque, this week. This approval represents a significant triumph for...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","IDNA","LABU","IE00BJT1NW94.SGD","BK4585","IE0002141913.USD","BK4139","CANC","LU0109394709.USD","IE00BFTCPJ56.SGD","LU0889565916.HKD","BK4588","LU0320765992.SGD","PTH","IE00BJJMRZ35.SGD","RVMD","IE00B4R5TH58.HKD","BBH","IE0009354923.USD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662762030","title":"Gilead Breaks Ground on Foster City Biologics Facility in $32 Billion US Investment Push","url":"https://stock-news.laohu8.com/highlight/detail?id=2662762030","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662762030?lang=en_us&edition=fundamental","pubTime":"2026-08-28 10:17","pubTimestamp":1787883449,"startTime":"0","endTime":"0","summary":"Gilead breaks ground on Foster City biologics facility in $32 billion US investment pushGilead broke ground on its Chess biologics facility at its Foster City, California headquarters as part of a pla","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nNDL98vB5b:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1037948897.HKD","IE0002270589.USD","LU0859254822.USD","LU0965508806.USD","LU0965509101.SGD","BMED","GILD","IBB","IE00BKVL7J92.USD","IE00B7SZLL34.SGD","LU1674673428.USD","LU1066053197.SGD","BIB","LU0234570918.USD","SG9999015952.SGD","LU1061106388.HKD","LU0109394709.USD","IE00B19Z3581.USD","BK4578","LU1430594728.SGD","LU1066051498.USD","LU1037948541.HKD","BK4568","LU0289739699.SGD","BBH","LU0861579265.USD","IBBQ","LU2357627491.SGD","LU2468319806.SGD","LU0058720904.USD","BK4532","LU0320765992.SGD","LU0823416689.USD","LU0965509283.SGD","IE00BSNM7G36.USD","LU2324357040.USD","LU1571399168.USD","LU0889565916.HKD","BK4583","TBXU","LU1934455194.USD","LU1674673691.USD","TMED","LU1057294990.SGD","LU2087621335.USD","MEDI","LU0965509010.AUD","LU2112291526.USD","LU1934455863.HKD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662037671","title":"Why the Drugmaker Behind a Pancreatic Cancer Breakthrough Stayed Independent","url":"https://stock-news.laohu8.com/highlight/detail?id=2662037671","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662037671?lang=en_us&edition=fundamental","pubTime":"2026-08-28 09:21","pubTimestamp":1787880060,"startTime":"0","endTime":"0","summary":"Earlier this year, an oncology biotech with no drugs on the market-just promising research-was attracting takeover interest. Revolution Medicines stayed independent.This week, that bet paid off.The 12","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","PTH","CANC","BBH","RVMD","IE0009355771.USD","LU0320765992.SGD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU0889565916.HKD","IE00BJJMRZ35.SGD","LU0109394709.USD","IE0009354923.USD","BK4139","IE00BJT1NW94.SGD","IDNA","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662394370","title":"Gilead Sciences Director Anthony Welters Disposes of USD 2.64 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2662394370","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662394370?lang=en_us&edition=fundamental","pubTime":"2026-08-28 06:45","pubTimestamp":1787870729,"startTime":"0","endTime":"0","summary":"Gilead Sciences director Anthony Welters disposes of USD 2.64 million in common sharesGilead director Anthony Welters exercised stock options for 18,000 shares on Aug. 26, 2026 at prices of USD 60.67 ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL29Bbzm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Gilead Sciences Director Anthony Welters Disposes of USD 2.64 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4578","LU0109394709.USD","TBXU","MEDI","BK4139","IE00B3T34201.USD","BK4583","IBB","BK4566","LU1066051498.USD","LU1061106388.HKD","GILD","LU0058720904.USD","LU1571399168.USD","BK4568","LU1057294990.SGD","BK4585","LU0289739699.SGD","BK4532","BBH","LU0889565916.HKD","LU1023059063.AUD","LU1585245621.USD","LU0965509101.SGD","BK4588","BMED","LU2087621335.USD","LU1430594728.SGD","BIB","IE00B19Z3581.USD","LU1839511570.USD","LU1934455863.HKD","LU2324357040.USD","LU1037948897.HKD","LU0965508806.USD","LU0320765992.SGD","LU0823416689.USD","IBBQ","IE00B19Z3B42.SGD","LU0861579265.USD","LU1674673428.USD","LU0965509010.AUD","IE00B7SZLL34.SGD","IE0002270589.USD","LU0859254822.USD","SG9999015986.USD","LU2112291526.USD","TMED","IE00BSNM7G36.USD","LU0122379950.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662036059","title":"Gilead’s Bixlenvo approved by FDA for virologically suppressed adults with HIV","url":"https://stock-news.laohu8.com/highlight/detail?id=2662036059","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662036059?lang=en_us&edition=fundamental","pubTime":"2026-08-28 05:55","pubTimestamp":1787867719,"startTime":"0","endTime":"0","summary":"Gilead (GILD) Sciences announced that the FDA approved Bixlenvo – bictegravir 75 mg/lenacapavir 50 mg -, the smallest once-daily single tablet regi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gileads-bixlenvo-approved-by-fda-for-virologically-suppressed-adults-with-hiv-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gileads-bixlenvo-approved-by-fda-for-virologically-suppressed-adults-with-hiv-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GILD","BK4566","LU0965509283.SGD","LU0109394709.USD","BK4532","BIB","LU1037948897.HKD","LU2357627491.SGD","BMED","LU1839511570.USD","LU1061106388.HKD","LU1934455194.USD","LU0889565916.HKD","TMED","LU1934455863.HKD","LABU","BBH","LU0823416689.USD","IBBQ","LU1066053197.SGD","IE00BSNM7G36.USD","IE00B19Z3B42.SGD","LU1674673428.USD","MEDI","LU1057294990.SGD","LU0234570918.USD","BK4588","SG9999015945.SGD","BK4583","BK4585","LU2324357040.USD","LU1674673691.USD","SG9999015952.SGD","LU0965509101.SGD","BK4139","TBXU","LU1066051498.USD","BK4568","IE00B19Z3581.USD","IE00BZ1G4Q59.USD","LU0859254822.USD","LU0861579265.USD","LU0122379950.USD","LU0058720904.USD","LU1023059063.AUD","SG9999015986.USD","IBB","LU1585245621.USD","LU2087621335.USD","LU1571399168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662036301","title":"US FDA Approves Gilead's Once-Daily Combination Pill for HIV Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2662036301","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662036301?lang=en_us&edition=fundamental","pubTime":"2026-08-28 05:50","pubTimestamp":1787867441,"startTime":"0","endTime":"0","summary":"US FDA approves Gilead's once-daily combination pill for HIV treatmentAug 27 -The U.S. Food and Drug Administration has approved Gilead Sciences'GILD.Oonce daily oral combination pill for treatment of adults whose HIV has already been reduced to very low levels, the company said on Thursday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL4N44O24M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002270589.USD","SG9999015945.SGD","LU0965509010.AUD","LU0114720955.EUR","LU2468319806.SGD","LU1934455277.USD","LU0889565916.HKD","BK4578","BK4588","LU0122379950.USD","IE00B19Z3581.USD","LU1023059063.AUD","IE00BZ1G4Q59.USD","LU0058720904.USD","LU0289739699.SGD","LU1934455863.HKD","BIB","IBBQ","LU0234570918.USD","LU1674673428.USD","LU2324357040.USD","MEDI","TBXU","LU1066051498.USD","LU1037948897.HKD","TMED","LU1061106388.HKD","LU1778281490.HKD","LU2357627491.SGD","BK4139","LU0861579265.USD","BBH","BK4585","LU1057294990.SGD","LU1585245621.USD","SG9999015952.SGD","GILD","BMED","BK4566","LU0882574055.USD","IE00B19Z3B42.SGD","IBB","LU0965508806.USD","LU1839511570.USD","BK4583","IE00B7SZLL34.SGD","IE00B3T34201.USD","LU0965509101.SGD","LU1037948541.HKD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662036807","title":"U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults with Hiv, Including Those on Complex Regimens","url":"https://stock-news.laohu8.com/highlight/detail?id=2662036807","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662036807?lang=en_us&edition=fundamental","pubTime":"2026-08-28 05:47","pubTimestamp":1787867220,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nTUA7M9KZ1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SG9999015978.USD","LU2468319806.SGD","LU0965509010.AUD","LU1066051498.USD","BK4578","IE00B19Z3B42.SGD","BK4550","LU0289739699.SGD","IBB","IBBQ","BK4583","LU0320765992.SGD","BIB","LU1066053197.SGD","LU2089984988.USD","BK4588","MEDI","BK4566","BMED","IE00BZ1G4Q59.USD","BK4532","IE00B3T34201.USD","BBH","LU0882574055.USD","LU1934455194.USD","IE00BKVL7J92.USD","TMED","IE00B7SZLL34.SGD","TBXU","LU1934455863.HKD","LU1839511570.USD","GILD","LU1430594728.SGD","LU0889565916.HKD","LU0965509283.SGD","LU1571399168.USD","LU1057294990.SGD","LU1934455277.USD","LU1037948897.HKD","LU0234570918.USD","LU0823416689.USD","LU2087621335.USD","SG9999015945.SGD","LU1778281490.HKD","BK4568","BK4585","LU0109394709.USD","LU2112291526.USD","LU1061106388.HKD","LU0861579265.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662033626","title":"Moderna Inc. Stock Slips 4.6%, Underperforms Peers","url":"https://stock-news.laohu8.com/highlight/detail?id=2662033626","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662033626?lang=en_us&edition=fundamental","pubTime":"2026-08-28 04:34","pubTimestamp":1787862840,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Moderna Inc. slid 4.6% to $142.77 on what proved to be an all-around positive trading session for the stock market, with the NASDAQ Composite Index rising 1.6% to 26,541.35 and the Dow Jones Industrial Average rising 0.2% to 53,569.44.This was the stock's second consecutive day of losses.Moderna Inc. closed 19.2% short of its 52-week high of $176.66, which the company reached on August 19th.The stock underperformed when compared to some of its peers, as Johnson & Johnson fell 1.6% to $265.77, Pfizer Inc. fell 1.0% to $28.02, and Gilead Sciences Inc. rose 0.52% to $148.86.Trading volume totaled 24.9 million, compared to the 50-day average of 16.4 million.Data source: Dow Jones Market Data, FactSet","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBB","LU1037948541.HKD","LU2324357040.USD","IDNA","LU0861579265.USD","SG9999015945.SGD","LU0058720904.USD","GNOM","IE00BKVL7J92.USD","BIB","BK4583","BK4550","LU2357627491.SGD","BK4568","BK4139","LU0114720955.EUR","LU1934455277.USD","LU1934455194.USD","TBXU","MEDI","LU2468319806.SGD","GILD","LU0109394709.USD","LU1674673691.USD","IE00B7SZLL34.SGD","LU1674673428.USD","LU0889565916.HKD","SG9999015952.SGD","BK4534","BK4588","LU0320765992.SGD","LU0965508806.USD","IBBQ","BK4551","LU1061106388.HKD","LU1066053197.SGD","MRNY","BBH","LU0965509010.AUD","MRNA","IE00B19Z3581.USD","BK4533","MRNX","BMED","SG9999015986.USD","LU0965509283.SGD","WDNA","LGHT","LU1571399168.USD","TMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662084187","title":"Amgen’s AMG 691 Phase 1 Trial Targets Key Growth in Asian Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2662084187","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662084187?lang=en_us&edition=fundamental","pubTime":"2026-08-28 00:31","pubTimestamp":1787848308,"startTime":"0","endTime":"0","summary":"Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen Inc. (AMGN) has started a new Phase 1 trial called “A Phase 1, Open-La...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/amgens-amg-691-phase-1-trial-targets-key-growth-in-asian-markets?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/amgens-amg-691-phase-1-trial-targets-key-growth-in-asian-markets?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PBE","LU0058720904.USD","LU1571399168.USD","BK4139","IE0002141913.USD","IE00BJJMRZ35.SGD","LU2242646821.SGD","LU0109394709.USD","IBBQ","BK4533","LU0122379950.USD","BBC","LU2468319806.SGD","LU2112291526.USD","BK4588","LU0320765992.SGD","LU1057294990.SGD","IE0009355771.USD","BK4566","IE00B4R5TH58.HKD","AMGN","TBXU","BK4599","PJP","SG9999001440.SGD","BIB","LU0889565916.HKD","LU2089984988.USD","LU1061106388.HKD","LU2242652126.USD","IBB","BK4581","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","BK4585","LU1983299246.USD","LU0289739699.SGD","LU0868494617.USD","LU1023059063.AUD","BBH","BK4534","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662008458","title":"Revolution Medicines' Rasonque Label Expands Commercial Opportunity, Oppenheimer Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2662008458","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662008458?lang=en_us&edition=fundamental","pubTime":"2026-08-28 00:21","pubTimestamp":1787847665,"startTime":"0","endTime":"0","summary":"Revolution Medicines (RVMD) receiving a broader-than-expected Food and Drug Administration label for Rasonque strengthens its commercial outlook, Oppenheimer said.Management emphasized that the label ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BJJMRZ35.SGD","BBH","IE00B4R5TH58.HKD","RVMD","CANC","IE00B2B36J28.USD","IE00BJT1NW94.SGD","BK4139","IDNA","LU0889565916.HKD","IE00BFTCPJ56.SGD","IE0009355771.USD","IE0002141913.USD","IE0009354923.USD","PTH","LU0320765992.SGD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662813780","title":"Analysts Offer Insights on Healthcare Companies: Verrica Pharmaceuticals (VRCA) and Amgen (AMGN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2662813780","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662813780?lang=en_us&edition=fundamental","pubTime":"2026-08-27 23:20","pubTimestamp":1787844046,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Verrica Pharmaceuticals (VRCA) and Amgen (AMGN). Verrica Pharmace...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-verrica-pharmaceuticals-vrca-and-amgen-amgn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-verrica-pharmaceuticals-vrca-and-amgen-amgn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","IBBQ","IE00BJT1NW94.SGD","LU1057294990.SGD","LU2468319806.SGD","LABU","AMGN","XLV","LU2089984988.USD","IBB","LU0109394709.USD","BIB","HCSG","BBH","IE00BJJMRZ35.SGD","LU2242646821.SGD","LU0122379950.USD","LU2112291526.USD","LU0058720904.USD","LU0868494617.USD","LU1571399168.USD","LU1023059063.AUD","IE00BFTCPJ56.SGD","BK4137","PBE","LU0029874061.USD","LU0128526141.USD","BK4581","BK4007","VRCA","TBXU","IE0009355771.USD","IE00B4R5TH58.HKD","BK4599","LU0889565916.HKD","BK4534","BK4139","XBI","LU2242652126.USD","BK4533","PJP","IE0002141913.USD","IE00B2B36J28.USD","LU1061106388.HKD","LU1983299246.USD","LU0289739699.SGD","BK4585","SG9999001440.SGD","BK4566","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662084083","title":"HBM Holdings FY26 H1 Profit Falls 11.16% to US$ 64.85 Million; Revenue Rises 20.9% to US$ 122.49 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662084083","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662084083?lang=en_us&edition=fundamental","pubTime":"2026-08-27 22:01","pubTimestamp":1787839287,"startTime":"0","endTime":"0","summary":"HBM Holdings FY26 H1 profit falls 11.16% to US$ 64.85 million; revenue rises 20.9% to US$ 122.49 millionHBM Holdings posted revenue of US$122.49 million for the six months ended June 30, 2026, up 20.9","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL77D5HK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","PJP","BBH","LU0868494617.USD","BK4139","LU1983299246.USD","LU2112291526.USD","BK4534","BK4588","IE00BFTCPJ56.SGD","LU0320765992.SGD","BK4533","LU2242652126.USD","02142","IE00BJJMRZ35.SGD","LU1061106388.HKD","IBB","LU1571399168.USD","LU2242646821.SGD","LU0058720904.USD","SG9999001440.SGD","PBE","BK1574","LU0889565916.HKD","LU1023059063.AUD","BK1583","LU2089984988.USD","IBBQ","TBXU","LU0122379950.USD","IE00BJT1NW94.SGD","BIB","IE0002141913.USD","BK4585","AMGN","IE00B2B36J28.USD","IE00B4R5TH58.HKD","BK4566","LU2468319806.SGD","LU1057294990.SGD","LU0109394709.USD","BK4599","BK4581","BK1161","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662704855","title":"Street View: Revolution's Pancreatic Cancer Drug Nod Sparks a 'transformative' Era","url":"https://stock-news.laohu8.com/highlight/detail?id=2662704855","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662704855?lang=en_us&edition=fundamental","pubTime":"2026-08-27 19:35","pubTimestamp":1787830554,"startTime":"0","endTime":"0","summary":"BUZZ-Street View: Revolution's pancreatic cancer drug nod sparks a 'transformative' era** Revolution Medicines'RVMD.Ogroundbreakingpancreatic cancer drug, Rasonque, received the U.S. FDA approval on W","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL4N44O10D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","IE0009354923.USD","IE00BJT1NW94.SGD","IE0009355771.USD","RVMD","IE0002141913.USD","IE00B4R5TH58.HKD","LU0320765992.SGD","IE00B2B36J28.USD","PTH","IDNA","BBH","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","LU0109394709.USD","BK4139","CANC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662013447","title":"Amgen, AstraZeneca announce Crossing trial showed ‘meaningful’ improvements","url":"https://stock-news.laohu8.com/highlight/detail?id=2662013447","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662013447?lang=en_us&edition=fundamental","pubTime":"2026-08-27 19:15","pubTimestamp":1787829352,"startTime":"0","endTime":"0","summary":"Positive high-level results from the Phase III CROSSING trial in patients with eosinophilic esophagitis showed that AstraZeneca (AZN) and Amgen’s (...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/amgen-astrazeneca-announce-crossing-trial-showed-meaningful-improvements-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/amgen-astrazeneca-announce-crossing-trial-showed-meaningful-improvements-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029864427.USD","BBH","LU2242652126.USD","BK4588","LU0868494617.USD","LU2237443622.USD","LU0432979614.USD","BK4139","AMGN","IBBQ","LU1829250122.USD","BK4581","AZN","LU2468319806.SGD","BK4534","LU2417539215.USD","BK4007","IE00B3T34201.USD","LU2237443978.SGD","LU0128525929.USD","LU2242646821.SGD","BK4568","IE00B4R5TH58.HKD","LU1057294990.SGD","LU2237443382.USD","IE00BJT1NW94.SGD","IE0002141913.USD","IE00B2B36J28.USD","LU2237443465.HKD","BIB","BK4533","TBXU","LU0122379950.USD","LU2462157665.USD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","PBE","PJP","LU0289739699.SGD","LU2456880835.USD","IE0009355771.USD","LU2236285917.USD","LU1023059063.AUD","AZNH","LU0708994859.HKD","LU1267930573.SGD","LU2089984988.USD","BK4566","BK4585","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662706801","title":"Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Immuneering (IMRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2662706801","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662706801?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:30","pubTimestamp":1787826622,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Revolution Medicines (RVMD) and Immuneering (IMRX) w...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-revolution-medicines-rvmd-and-immuneering-imrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-revolution-medicines-rvmd-and-immuneering-imrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0109394709.USD","IE0009354923.USD","IE00BJT1NW94.SGD","BK4139","IE0002141913.USD","PTH","BK4137","XBI","BK4539","CANC","HCSG","LU0320765992.SGD","RVMD","BK4563","IE00BFTCPJ56.SGD","IMRX","IE00B4R5TH58.HKD","BK4585","LABU","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0029874061.USD","BK4581","LU0889565916.HKD","BBH","LU0128526141.USD","BK4588","IDNA","XLV","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662708043","title":"China's JW Therapeutics Interim Revenue Rises 4.7% on Carteyva Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2662708043","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662708043?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:08","pubTimestamp":1787825320,"startTime":"0","endTime":"0","summary":"China's JW Therapeutics interim revenue rises 4.7% on Carteyva salesOverviewChina cell immunotherapy developer's interim revenue grew 4.7% yr/yr, driven by Carteyva salesGross profit margin improved t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL1N44O0DW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABBV","LU0395794307.EUR","BBH","LU0463099449.HKD","IBB","IBBQ","IE0004445239.USD","LU1934455277.USD","LU2237443382.USD","LU2237443978.SGD","LU2097828714.EUR","XLV","MEDX","LU1037948897.HKD","RXL","IE00BVYPNV92.GBP","02126","LU0868494617.USD","LU1934455863.HKD","IE000SO60NU8.SGD","IYH","IE00BN8TJ469.HKD","REGN","TRUH","FHLC","PJP","LU0859254822.USD","FTXH","LU1188198961.HKD","LU0310799852.SGD","CMI","AGNG","PPH","TBXU","LU0949170772.SGD","BK1574","GLAM","LU0943347566.SGD","VHT","688331","KURE","LU2362541513.USD","LU0708994859.HKD","MADE","LU1244550577.SGD","03692","01801","IXJ","JDOC","LU0432979614.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662708397","title":"JW Cayman Therapeutics FY26 H1 IFRS Loss Narrows 81.14% to RMB 50.4 Million; Revenue Rises 4.7% to RMB 111.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662708397","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662708397?lang=en_us&edition=fundamental","pubTime":"2026-08-27 17:58","pubTimestamp":1787824692,"startTime":"0","endTime":"0","summary":"JW Cayman Therapeutics FY26 H1 IFRS loss narrows 81.14% to RMB 50.4 million; revenue rises 4.7% to RMB 111.4 millionJW Cayman Therapeutics posted IFRS revenue of RMB 111.4 million, up 4.7% year over y","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL8Yh1j4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02126","LU0053666078.USD","BK1583","LU0058720904.USD","LU2362540622.SGD","BK4588","LU0823416689.USD","LU2106854487.HKD","LU0320765992.SGD","LU0289739699.SGD","REGN","BK4139","LU2362541513.USD","LU0109394709.USD","LU0114720955.EUR","LU0889565916.HKD","LU0823434583.USD","BBH","LU2237438978.USD","LU2089984988.USD","LU2468319806.SGD","LU0882574055.USD","LU1917777945.USD","BK4585","TBXU","IBBQ","LU0823434740.USD","LU2023250504.SGD","LU2362541273.HKD","IBB","LU1974910355.USD","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":200,"code":"91000000","status":"200"}]}}